Catheterization Lab Equipment in Florida

ALN Implants Chirurgicaux manufactures inferior vena cava (IVC) filters for temporary and permanent placement in vascular interventional procedures. Their product line includes the OATF Optional Vena Cava Filter, designed for both permanent and temporary use, with support for popliteal approach insertion. The company offers a 2-in-1 removal and repositioning kit (RK-2010) enabling filter retrieval via jugular approach and repositioning capability if clinically indicated. Clinical evidence demonstrates successful retrieval of ALN filters at 25.6 months post-placement, supporting both acute and extended-dwell applications. The company markets to interventional radiologists and vascular surgeons globally, with FDA approval indicated on their website. Products are designed with emphasis on safe handling, procedural efficiency, and retrieval reliability. The website indicates regulatory compliance and quality engagement protocols aligned with medical device manufacturing standards.

OrbusNeich Medical is a Hong Kong-based manufacturer of innovative vascular intervention devices for the treatment of coronary and peripheral vascular disease. The company specializes in designing and delivering high-performance balloon catheters, stents, and specialty catheters for interventional cardiology and peripheral vascular procedures. OrbusNeich operates two primary product portfolios: Coronary (for treating heart vessel disease) and Peripheral (for treating non-coronary vascular conditions). The company emphasizes physician partnership in product development and clinical application, positioning itself as a leader in vascular device innovation. OrbusNeich maintains active engagement in international cardiology conferences and medical societies, including EuroPCR, the Oriental Congress of Cardiology, and regional vascular surgery meetings. The company demonstrates commitment to patient education and long-term quality-of-life outcomes. Products are designed for interventional cardiologists and vascular surgeons. No specific regulatory certifications (FDA 510(k), ISO, CE Mark) are explicitly mentioned on the homepage, though such devices typically require FDA clearance and CE marking for European distribution.

Marizyme, Inc. is a biomedical company specializing in the development and commercialization of medical technologies for vascular preservation and protection. The company is best known for DuraGraft®, the first and only FDA-cleared solution designed for the flushing and storage of saphenous vein grafts during Coronary Artery Bypass Grafting (CABG) procedures. DuraGraft is formulated to reduce oxidative damage during intraoperative storage, maintain cell viability, and preserve structural integrity of vein grafts. Clinical evidence demonstrates that saphenous vein grafts stored in DuraGraft exhibit significantly less wall thickening at 12 months post-CABG compared to those stored in saline. The company leverages proprietary enzyme technology and bioengineering expertise to address critical challenges in vascular graft preservation, offering solutions that improve patient outcomes in cardiothoracic surgery.

Omega Medical Imaging, LLC manufactures AI-enabled interventional imaging systems designed to reduce radiation exposure in cardiology and gastroenterology procedures. The company's core technology platform, FluoroShield™, functions as a secondary collimator using artificial intelligence to establish a Region of Interest (ROI), reducing unnecessary radiation to peripheral anatomy while maintaining image quality. Products include Soteria.AI for cardiac catheterization labs and E-View.AI for endoscopy systems, both incorporating real-time AI image guidance. The company reports radiation dose reductions up to 84% compared to conventional fluoroscopy. Omega Medical Imaging is FDA-approved for their AI-enabled X-ray systems and manufactures equipment in the United States. The company serves interventional cardiologists, gastroenterologists, and hospital interventional labs. Product lines include cardiac systems (fluoroscopy for catheterization procedures), endoscopy systems (GI/ERCP), electrophysiology labs, and surgical displays. The company emphasizes workflow integration, enabling seamless AI detection without interrupting clinical procedures. Additionally featured are TruBlock™ technology for ROI concentration and advanced image processing for both cine and fluoroscopy modes.

Medical Trade Center (MTC) is an FDA-registered medical equipment distributor and service provider specializing in diagnostic imaging systems with over 20 years of industry experience. The company maintains an extensive global inventory of 200+ diagnostic systems and 30,000+ replacement parts, all tested and validated before shipment. MTC's core business focuses on GE Nuclear Medicine and MRI systems, with a strong secondary business in CT and PET imaging equipment. The company provides comprehensive services including full-system refurbishment, application software integration, operator training, field engineering support, and complete logistics management (inspection, deinstallation, crating, rigging, transport, customs facilitation, and on-site installation). MTC serves hospitals, diagnostic imaging centers, and medical equipment partners worldwide, with a significant portion of revenue derived from repeat customers. The organization includes factory-trained support specialists and experienced field engineers dedicated to GE systems. Project coordination is managed by dedicated project managers who oversee entire workflows from equipment acquisition through installation. The company emphasizes customer success through professional handling, reliable support, and transparent pricing. MTC also facilitates equipment resale services for institutions looking to upgrade or divest used systems.

Zimmer Biomet CMF and Thoracic (CMF&T) is a division of Zimmer Biomet specializing in thoracic and chest wall surgical solutions. The company develops rigid fixation systems, wire closure products, and minimally invasive surgical devices for sternal closure, rib fracture stabilization, and pectus excavatum repair. Product portfolio includes the SternaLock® family (SternaLock Blu, SternaLock XP, SternaLock 360, SternaLock EZ), RibFix® systems (RibFix Blu, RibFix Advantage), and pectus repair solutions (Pectus Bar, Adkins Strut, Pectus Blu). The company also offers cardiovascular products including temporary pacing wires and surgical punches. Clinical evidence supporting products includes the randomized controlled SternaLock Blu Study (236 patients, 2014–2015) demonstrating improved sternal healing, reduced complications, and cost savings versus wire cerclage. The company markets to cardiothoracic surgeons, trauma surgeons, and hospital OR teams. Zimmer Biomet holds regulatory approvals including Japanese approval and reimbursement for SternaLock Blu. Manufacturing and quality documentation available on site.

Encore Medical, Inc. is a cardiovascular device company specializing in transcatheter closure devices for congenital heart defects. Founded in October 2020, the company builds on over 20 years of international transcatheter closure device experience, with more than 25,000 devices successfully implanted globally. Encore's primary product portfolio includes the Encore Patent Foramen Ovale (PFO) Closure Device and the Encore Atrial Septal Defect (ASD) Closure Device, both designed for percutaneous, catheter-based implantation to close abnormal communications between cardiac chambers. The Encore PFO device prevents embolic stroke by closing unwanted communications between right and left atria, offering features including full retrievability, minimal blood flow disturbance, and conformance to patient anatomy. The Encore ASD device provides similar closure capabilities for atrial septal defects in pediatric and adult patients across multiple sizing options. Both devices are supported by the proprietary Encore Delivery System, a catheter-based platform available in multiple French sizes (9–12 Fr) with self-sealing introducers and positive locking mechanisms for device release. The company is currently conducting the PerFOrm randomized controlled trial comparing the Encore PFO device to FDA-approved alternatives, intended to support US regulatory approval. Encore's devices are based on patented technology platforms with demonstrated clinical performance outside the United States. The company operates from Eagan, Minnesota, and focuses on interventional cardiology and structural heart disease markets.

Venocare, Inc. is a medical device company specializing in innovative vascular access solutions. The company develops and markets peripheral intravenous catheter (PIVC) devices and related blood collection systems designed to improve patient comfort, clinician efficiency, and insertion success rates. Their primary products include Ruby™, a soft-tip guided PIVC featuring a proprietary needle and guidewire assembly engineered to achieve greater first-attempt insertion success with reduced patient discomfort, and Navi™, a needle-free blood collection device compatible with most PIVC systems that eliminates traditional needle-based blood draws. Venocare's technology platform prioritizes safety, precision, and ease of use in the vascular access workflow. The company is positioned in the peripheral vascular access market, serving acute care, hospital, and clinical environments where reliable IV access and blood collection are critical care components. Manufacturing and regulatory details indicate FDA clearance or approval of their devices for clinical use. Venocare emphasizes reducing complications associated with traditional vascular access methods while maintaining clinician control and system compatibility.

Integer Holdings Corporation (NYSE: ITGR) is a global leader in medical device contract development and manufacturing (CDMO), with 80+ years of expertise in advanced medical device design, outsourcing, and component manufacturing. The company specializes in cardiac rhythm management, neuromodulation, vascular access, and cardiovascular devices. Integer operates through subsidiary brands Greatbatch Medical and Lake Region Medical, serving major global OEM medical device manufacturers across multiple therapeutic markets. The company designs and manufactures finished device systems and Class III medical devices, including catheters, guidewires, introducers, delivery systems, tantalum capacitors, implantable and external batteries, pacemaker batteries, implantable ports, and neuromodulation devices. Integer operates a vertically integrated supply chain with global R&D and manufacturing capabilities across four continents, supporting rapid prototyping, product development, testing and regulatory certification, product lifecycle management, and on-time delivery. The company serves 15+ medical device markets including cardiac rhythm management, neuromodulation, vascular access, cardiovascular, structural heart, electrophysiology, peripheral vascular, neurovascular, oncology, urology, infusion therapy, and hemodialysis. Integer is a manufacturing excellence organization with deep expertise in regulatory compliance, quality standards, and design optimization to minimize risk and accelerate time-to-market for OEM partners.

XS Supply is a distributor of OEM surgical supplies and single-use surgical instruments sourced from surplus hospital and manufacturer inventory. The company serves hospitals, surgery centers, and healthcare procurement professionals throughout Florida and nationally. XS Supply offers genuine sealed, sterile products from major manufacturers including Intuitive Surgical, Medtronic, Applied Medical, Stryker, Smith & Nephew, Arthrex, Alcon, and 50+ other OEM brands at 20–40% savings versus standard OEM pricing. Product categories include robotics and endomechanical instruments, laparoscopic and endoscopic devices, orthopedic surgical supplies, ENT instruments, cardiac and vascular supplies, neurosurgery implants, obstetric and gynecologic tools, ophthalmology instruments, and urology products. The company specializes in single-unit purchasing without case minimums or long-term contracts, emergency sourcing for backordered items, and same-day delivery within most Florida metro areas. XS Supply also operates a surplus inventory buyback program, purchasing excess stock directly from hospitals and healthcare facilities. The company serves 500+ healthcare facilities and maintains access to 3,000+ unique SKUs. No specific regulatory certifications (FDA 510(k), ISO) are mentioned on the website.

MedSupply Inc. is a Florida-based medical device distributor specializing in disposable medical supplies for both public and healthcare industry clients. The company maintains ACHC accreditation and offers a comprehensive portfolio of advanced wound dressings, impregnated dressings with medical-grade materials (including manuka honey-infused gauze and silicone-bordered products), home medical equipment, and cardiovascular products including catheterization supplies. MedSupply distributes quality solutions across wound care, ostomy, urinary, and surgical support categories, with emphasis on products that promote optimal healing environments and patient comfort. The company actively develops and sources innovative products to advance wound care standards and improve patient outcomes across clinical and home-care settings.

Twins & Martin is a leading global distributor of medical devices specializing in endovascular therapy solutions. The company provides a comprehensive portfolio of products spanning peripheral vascular, cardiovascular, venous, and interventional radiology applications, serving healthcare facilities across more than 30 countries for over 30 years. BMC Medical Manufacturing operates as part of Twins & Martin's distribution network, focusing on high-quality medical technology solutions including guide wires, balloon catheters, vascular stents, and catheterization lab equipment. The company emphasizes innovation, quality assurance, regulatory compliance (FCPA, UK Bribery Act), and customer service to support better patient outcomes in endovascular interventional procedures.

InspireMD, Inc. is a medical device manufacturer specializing in carotid intervention and stroke prevention. The company develops and markets the CGuard® and CGuard® Prime carotid stent systems, which feature dual-layer designs combining a conformable self-expanding stent with a protective non-metallic MicroNet™ mesh covering. The CGuard Prime system is indicated for improving carotid luminal diameter in high-risk patients requiring carotid revascularization, addressing the significant clinical problem of plaque prolapse and late embolization during carotid artery stenting (CAS) procedures. According to pivotal trial data (C-GUARDIANS), CGuard Prime demonstrated 0.95% 30-day and 1.93% 1-year major adverse event rates (composite of death, any stroke, or myocardial infarction), among the lowest independently adjudicated rates in carotid stenting literature. The system is designed for vessel reference diameters between 6.4 mm and 9.0 mm and is used in conjunction with embolic protection devices including Abbott Emboshield NAV6 or Medtronic Mo.Ma Ultra. InspireMD maintains USA headquarters in Miami, Florida, with manufacturing operations in Israel and EU representation through Obelis s.a. in Brussels. The company serves interventional cardiologists, vascular surgeons, and endovascular specialists globally, with regulatory clearance for sale in the United States and Europe. Product design emphasizes SmartFit flexibility for variable anatomy and MicroNet mesh for enhanced plaque prolapse prevention.

ICHOR Vascular Inc. is a medical device manufacturer specializing in minimally invasive clot removal technology for peripheral vascular occlusions. The company develops the iSWEEP platform—an all-in-one endovascular thrombectomy and embolic protection system that modernizes the traditional Fogarty balloon sweep technique. The iSWEEP combines an occlusion balloon, expandable guide catheter with nitinol funnel, and rapid exchange balloon catheter into a self-contained, three-component system requiring no lytics, additional components, or capital equipment. FDA 510(k) cleared products include the iART 7F System for arterial applications and the iDVT 14F System for venous reperfusion. The technology treats vessel sizes from 4mm to 14mm and addresses both arterial and venous clot pathology. Designed for vascular interventionalists, iCHOR's systems aim to simplify peripheral clot removal while reducing procedural complexity, patient trauma, and operative cost compared to surgical thrombectomy or pharmacological thrombolysis.

NuMED, Inc. is a 35+ year established manufacturer of innovative cardiovascular medical devices specializing in minimally invasive interventional solutions for congenital heart defects and peripheral vascular disease. The company manufactures over 26 interventional brands distributed across more than 100 countries globally. NuMED's comprehensive product portfolio focuses on pediatric interventional cardiology, including advanced balloon catheter systems, stent technologies, and catheterization lab equipment designed for diagnostic and therapeutic procedures. The company is committed to collaborating with global thought leaders and interventionalists to develop high-quality, clinically superior devices that improve patient outcomes in congenital heart treatment. With a strong presence in the international interventional community and founding sponsorship of PICS (Pediatric Interventional Cardiology Society) since 1997, NuMED combines decades of manufacturing expertise with ongoing innovation in catheter design, stent delivery systems, and hemodynamic interventional tools.

SkyDance Vascular manufactures the OspreyIV, a proprietary through-the-needle peripheral vascular access device designed to address complications associated with traditional over-the-needle catheters. The OspreyIV features four core innovations: (1) Skin Avoidance Technology—the catheter passes through rather than over the needle, preventing skin contact and reducing infection risk from bacterial colonization; (2) Bevel Only Technique—enabling single-attempt insertion success and minimizing vessel trauma and phlebitis; (3) Passive Needle Retraction—automatic needle retraction into housing post-insertion, eliminating sharps handling and needlestick injury risk; and (4) Contoured Directional Flow—off-axis fluid delivery away from the venous wall to reduce infiltration, phlebitis, and chemical irritation. The OspreyIV product line includes peripheral IV, peripheral closed IV, and midline closed IV catheter systems. Aligned with Aseptic Non-Touch Technique (ANTT) principles, the technology is designed to reduce catheter-related bloodstream infections (estimated 200,000 annually in the U.S., costing ~$6B), vessel damage, and clinical complications across adult, pediatric, and neonatal populations. B2B-focused supplier for hospitals, health systems, and acute-care facilities.